<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01339897</url>
  </required_header>
  <id_info>
    <org_study_id>N6022-1H1-03</org_study_id>
    <nct_id>NCT01339897</nct_id>
  </id_info>
  <brief_title>A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study Evaluating the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of N6022 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nivalis Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nivalis Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1 study will evaluate multiple doses across a range that has been found to be
      effective in mouse models of asthma and safe in one Phase 1 clinical trial. It is intended to
      provide evidence of the tolerability of multiple doses as well as provide information on the
      Pharmacokinetic (PK) and metabolism of N6022 in humans.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, randomized, placebo-controlled, multiple ascending dose study, in at
      least three ascending cohorts. Twenty-four subjects will be enrolled initially in the first
      three cohorts, with up to 40 subjects to be enrolled overall if additional cohorts are
      required to reach the maximum tolerated dose (MTD). The cohorts will be enrolled in two
      groups of 4 each with approximately 7 days between groups to conduct safety monitoring
      committee review for approval to proceed to the second group in the cohort. Eight subjects
      will be enrolled per cohort, randomized 3:1 to N6022: placebo. Each subject will undergo
      screening (Day -28 to Day -2) and, if eligible, they will be instructed to begin a
      low-nitrate diet on Day -4. Subjects will return to the clinical site on Day -1, and
      eligibility will be reconfirmed. Eligible subjects will receive a dose of investigational
      medicinal product ([IMP], N6022 or placebo) by intravenous (IV) infusion on study Days 1
      through 7 and will be followed for safety, PK, and PD until discharge on the morning of Day
      8. Subjects will return to the clinic for a follow-up visit on Day 15 (± 1 day) and will be
      contacted via telephone on Day 28 (± 1 day) for the end-of-study safety follow-up visit.
      Participation of an individual subject may last approximately 56 days from the time of
      screening until the end-of-study follow-up visit.

      A Safety Monitoring Committee (SMC) will review the safety data in each cohort after the Day
      15 Follow-up visit, before proceeding to the next ascending dose cohort, modifying the dose,
      repeating a dose, or stopping the study according to the stopping rules outlined in the
      protocol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Escalating Multiple Doses of N6022 in Healthy Subjects</measure>
    <time_frame>Over 7 days</time_frame>
    <description>Safety variables (adverse events, vital signs, physical examination, telemetry, 12-lead ECG, infusion site reactions, O2 saturation, and clinical laboratory assessments)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of N6022</measure>
    <time_frame>Day 1, 24 hours</time_frame>
    <description>N6022 AUC0-tau measurements from Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of N6022 Over 7 Days</measure>
    <time_frame>Day 7, 24 hours</time_frame>
    <description>Analysis of N6022 AUC0-tau values from Study Day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of N6022 on Study Day 1</measure>
    <time_frame>Day 1, 24 hours</time_frame>
    <description>Analysis of N6022 Cmax values on Study Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of N6022 Cmax Values on Study Day 7</measure>
    <time_frame>Day 7, 24 hours</time_frame>
    <description>Pharmacokinetic Analysis of N6022 Cmax values on Study Day 7</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>5 mg/N6022</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injectable formulation, given at doses per cohort of 5 mg given QD each day over 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Injectable formulation normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10mg/N6022</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injectable formulation, given at doses of 10 mg given QD each day over 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20mg/N6022</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injectable formulation, given at doses per cohort of 20 mg given QD each day over 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 mg/N6022</intervention_name>
    <description>Intravenous formulation, given at doses of 5 mg once each day over 7 days.</description>
    <arm_group_label>5 mg/N6022</arm_group_label>
    <other_name>N6022</other_name>
    <other_name>GSNOR Inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Same administration procedures as active</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10mg/N6022</intervention_name>
    <description>Intravenous formulation given at doses of 10 mg once each day over 7 days.</description>
    <arm_group_label>10mg/N6022</arm_group_label>
    <other_name>N6022</other_name>
    <other_name>GSNOR Inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20mg/N6022</intervention_name>
    <description>Intravenous formulation given at doses of 20 mg once each day over 7 days.</description>
    <arm_group_label>20mg/N6022</arm_group_label>
    <other_name>N6022</other_name>
    <other_name>GSNOR Inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is healthy, determined by pre-study medical evaluation (medical history,
             physical examination, vital signs, 12-lead ECG, and clinical laboratory evaluations

          2. Subject is a non-smoker (or other nicotine user) as determined by history (no nicotine
             use over the past year) and a negative urine cotinine test at screening and Day 1.

          3. Subject has a body weight &gt; 50 kg and BMI between 19.5 and 29.5 kg/m2, inclusive, at
             screening.

          4. Subject has systolic BP &gt; 90 mmHg and diastolic BP &gt; 50 mmHg at screening or Day-1.

        Exclusion Criteria:

          1. Subject has clinically significant history or evidence of cardiovascular, respiratory,
             hepatic, renal, gastrointestinal, endocrine, neurological, immunological, or
             psychiatric disorder(s) as determined by the investigator or designee.

          2. Subject is a current alcohol abuser and/or has a history of illicit drug abuse within
             six months of entry.

          3. Subject has donated blood (&gt; 500 mL) or blood products within 56 days prior to Day -1.

          4. Subject has a history of bleeding disorders (i.e., severe hemorrhage, melena, rectal
             bleeding, nosebleeds, bruising, etc.).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Goldwater, MDCM, MSc(A)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parexel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel International</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2011</study_first_submitted>
  <study_first_submitted_qc>April 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2011</study_first_posted>
  <results_first_submitted>November 26, 2013</results_first_submitted>
  <results_first_submitted_qc>January 15, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 19, 2015</results_first_posted>
  <last_update_submitted>January 15, 2015</last_update_submitted>
  <last_update_submitted_qc>January 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>N6022, GSNORi</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment occurred between 06April2011 and 09August2011. This study was done at a single Phase 1 site.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>5 mg/N6022</title>
          <description>Active Group- 5 mg by IV administration (5 mg/minute)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Non-Active</description>
        </group>
        <group group_id="P3">
          <title>10 mg/N6022</title>
          <description>Active Group- 10 mg by IV administration (5 mg/minute)</description>
        </group>
        <group group_id="P4">
          <title>20 mg/N6022</title>
          <description>Active Group- 20 mg by IV administration (5 mg/minute)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized subjects who received any amount of IMP</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1</title>
          <description>N6022 - Active 5 mg</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2</title>
          <description>N6022 - Active 10 mg</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3</title>
          <description>N6022 - Active 20 mg</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Non-Active</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" lower_limit="25" upper_limit="39"/>
                    <measurement group_id="B2" value="31" lower_limit="22" upper_limit="45"/>
                    <measurement group_id="B3" value="35" lower_limit="22" upper_limit="45"/>
                    <measurement group_id="B4" value="35" lower_limit="25" upper_limit="45"/>
                    <measurement group_id="B5" value="33" lower_limit="22" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety of Escalating Multiple Doses of N6022 in Healthy Subjects</title>
        <description>Safety variables (adverse events, vital signs, physical examination, telemetry, 12-lead ECG, infusion site reactions, O2 saturation, and clinical laboratory assessments)</description>
        <time_frame>Over 7 days</time_frame>
        <population>Any subject that received any dose of N6022 or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>N6022 - Active 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>N6022 Active - 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>N6022 - Active 20 mg</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Non-Active</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of Escalating Multiple Doses of N6022 in Healthy Subjects</title>
          <description>Safety variables (adverse events, vital signs, physical examination, telemetry, 12-lead ECG, infusion site reactions, O2 saturation, and clinical laboratory assessments)</description>
          <population>Any subject that received any dose of N6022 or placebo.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of subjects on study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Early Termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of N6022</title>
        <description>N6022 AUC0-tau measurements from Day 1</description>
        <time_frame>Day 1, 24 hours</time_frame>
        <population>Any subject that completed N6022 or placebo PK sampling</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>N6022 Active - 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>N6022 Active - 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>N6022 Active - 20 mg</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Non-Active</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of N6022</title>
          <description>N6022 AUC0-tau measurements from Day 1</description>
          <population>Any subject that completed N6022 or placebo PK sampling</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138" spread="13.0"/>
                    <measurement group_id="O2" value="334" spread="21.1"/>
                    <measurement group_id="O3" value="669" spread="16.9"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of N6022 Over 7 Days</title>
        <description>Analysis of N6022 AUC0-tau values from Study Day 7</description>
        <time_frame>Day 7, 24 hours</time_frame>
        <population>N6022 AUC0-tau values from Study Day 7</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>N6022 Active - 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>N6022 Active - 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>N6022 Active - 20 mg</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Non-Active</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of N6022 Over 7 Days</title>
          <description>Analysis of N6022 AUC0-tau values from Study Day 7</description>
          <population>N6022 AUC0-tau values from Study Day 7</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149" spread="24.6"/>
                    <measurement group_id="O2" value="367" spread="14.2"/>
                    <measurement group_id="O3" value="811" spread="11.3"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of N6022 on Study Day 1</title>
        <description>Analysis of N6022 Cmax values on Study Day 1</description>
        <time_frame>Day 1, 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>N6022 Active - 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>N6022 Active - 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>N6022 Active - 20 mg</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Non-Active</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of N6022 on Study Day 1</title>
          <description>Analysis of N6022 Cmax values on Study Day 1</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="465" spread="69.8"/>
                    <measurement group_id="O2" value="1270" spread="95.6"/>
                    <measurement group_id="O3" value="1400" spread="86.2"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of N6022 Cmax Values on Study Day 7</title>
        <description>Pharmacokinetic Analysis of N6022 Cmax values on Study Day 7</description>
        <time_frame>Day 7, 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>N6022 Active - 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>N6022 Active - 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>N6022 Active - 20 mg</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Non-Active</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of N6022 Cmax Values on Study Day 7</title>
          <description>Pharmacokinetic Analysis of N6022 Cmax values on Study Day 7</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="287" spread="89.8"/>
                    <measurement group_id="O2" value="1110" spread="34.1"/>
                    <measurement group_id="O3" value="2320" spread="13.5"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 Days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1</title>
          <description>N6022 - Active 5 mg</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2</title>
          <description>N6022 Active - 10 mg</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3</title>
          <description>N6022 - Active 20 mg</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Non-Active</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular Arrythmia</sub_title>
                <description>Isolated episode, non-sustained</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo Positional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Aphthous Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>administration and site conditions</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection Site Extravasation</sub_title>
                <description>administration and site conditions</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>administration and site conditions</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vessel Puncture Site Hematoma</sub_title>
                <description>administration and site conditions</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection Site Induration</sub_title>
                <description>administration and site conditions</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <description>administration and site conditions</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis Externa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Upper Respiratory tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Traumatic Hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Magnesium Abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculosketetal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pre-syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Contact Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis Superficial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator agrees with the use of results of the clinical study for the purposes of national and international registration, publication, and information for medical and pharmaceutical professionals. If necessary, the competent authorities will be notified of the investigator’s name, address, qualifications, and extent of involvement. An investigator shall not publish any data (poster, abstract, paper, etc.) without having consulted with the Sponsor in advance.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Janice M Troha</name_or_title>
      <organization>N30 Pharmaceuticals Inc.</organization>
      <phone>720-945-7714</phone>
      <email>janice.troha@n30pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

